0000939767-19-000204.txt : 20191206
0000939767-19-000204.hdr.sgml : 20191206
20191206192328
ACCESSION NUMBER: 0000939767-19-000204
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20191204
FILED AS OF DATE: 20191206
DATE AS OF CHANGE: 20191206
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Schwab Gisela
CENTRAL INDEX KEY: 0001213140
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 000-30235
FILM NUMBER: 191274073
MAIL ADDRESS:
STREET 1: 6701 KAISER DRIVE
CITY: FREMONT
STATE: CA
ZIP: 94555
FORMER NAME:
FORMER CONFORMED NAME: SCHWAB GISELA MD
DATE OF NAME CHANGE: 20030107
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: EXELIXIS, INC.
CENTRAL INDEX KEY: 0000939767
STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-COMMERCIAL PHYSICAL & BIOLOGICAL RESEARCH [8731]
IRS NUMBER: 043257395
STATE OF INCORPORATION: DE
FISCAL YEAR END: 0103
BUSINESS ADDRESS:
STREET 1: 1851 HARBOR BAY PARKWAY
CITY: ALAMEDA
STATE: CA
ZIP: 94502
BUSINESS PHONE: 6508377000
MAIL ADDRESS:
STREET 1: 1851 HARBOR BAY PARKWAY
CITY: ALAMEDA
STATE: CA
ZIP: 94502
FORMER COMPANY:
FORMER CONFORMED NAME: EXELIXIS INC
DATE OF NAME CHANGE: 20000207
FORMER COMPANY:
FORMER CONFORMED NAME: EXELIXIS PHARMACEUTICALS INC
DATE OF NAME CHANGE: 20000106
4
1
wf-form4_157567819018369.xml
FORM 4
X0306
4
2019-12-04
0
0000939767
EXELIXIS, INC.
EXEL
0001213140
Schwab Gisela
C/O EXELIXIS, INC.
1851 HARBOR BAY PARKWAY
ALAMEDA
CA
94502
0
1
0
0
Pres, Prod Dev & Med Aff & CMO
Common Stock
2019-12-04
4
A
0
15592
0
A
329149
D
Common Stock
2019-12-04
4
F
0
4027
17.67
D
325122
D
Common Stock
14880
I
By 401(k)
Represents shares of Exelixis, Inc. common stock issued to the Reporting Person upon vesting of restricted stock units. Each restricted stock unit is the economic equivalent of one share of Exelixis, Inc. common stock.
On September 10, 2018, the Reporting Person was granted a performance-based restricted stock unit ("PSU") award of 15,592 shares of common stock under the Exelixis, Inc. 2017 Equity Incentive Plan. Vesting of the PSU award is tied to performance goals set by the Compensation Committee (the "Committee") as follows: (i) 50% of the original number of shares subject to the award will vest upon the Committee's certification that Exelixis, Inc. has achieved a net product revenue target over four consecutive fiscal quarters; and (ii) 50% of the original number of shares subject to the award will vest on the first quarterly PSU vesting date (i.e. February 15th, May 15th, August 15th and November 15th) following the one-year anniversary of the Committee's certification.
On December 4, 2019, the Committee convened to determine that the net product revenue target over four consecutive fiscal quarters had been achieved during the three months ended September 27, 2019, resulting in the immediate vesting of 50% of the PSU award, and the remaining 50% will vest on February 15, 2021, subject to the Reporting Person's continuous service through that date.
Includes 55,494 shares of Exelixis, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units.
Shares withheld by Exelixis, Inc. to satisfy taxes payable in connection with the vesting of certain restricted stock units earned on December 4, 2019.
Represents shares of Exelixis, Inc. common stock under the Exelixis, Inc. 401(k) Plan, pursuant to a plan statement dated as of December 3, 2019.
/s/ Jennifer Drimmer Rokovich, Attorney in Fact
2019-12-06